Cue Biopharma, Inc. - FORM S-1 - EX-23.1 - EXHIBIT 23.1 - September 21, 2017

Attached files

file filename
EX-10.5 - EXHIBIT 10.5 - Cue Biopharma, Inc.v475194_ex10-5.htm
EX-10.19 - EXHIBIT 10.19 - Cue Biopharma, Inc.v475194_ex10-19.htm
EX-10.18 - EXHIBIT 10.18 - Cue Biopharma, Inc.v475194_ex10-18.htm
EX-10.17 - EXHIBIT 10.17 - Cue Biopharma, Inc.v475194_ex10-17.htm
EX-10.16 - EXHIBIT 10.16 - Cue Biopharma, Inc.v475194_ex10-16.htm
EX-10.15 - EXHIBIT 10.15 - Cue Biopharma, Inc.v475194_ex10-15.htm
EX-10.14 - EXHIBIT 10.14 - Cue Biopharma, Inc.v475194_ex10-14.htm
EX-10.13 - EXHIBIT 10.13 - Cue Biopharma, Inc.v475194_ex10-13.htm
EX-10.11 - EXHIBIT 10.11 - Cue Biopharma, Inc.v475194_ex10-11.htm
EX-10.10 - EXHIBIT 10.10 - Cue Biopharma, Inc.v475194_ex10-10.htm
EX-10.9 - EXHIBIT 10.9 - Cue Biopharma, Inc.v475194_ex10-9.htm
EX-10.8 - EXHIBIT 10.8 - Cue Biopharma, Inc.v475194_ex10-8.htm
EX-10.7 - EXHIBIT 10.7 - Cue Biopharma, Inc.v475194_ex10-7.htm
EX-10.6 - EXHIBIT 10.6 - Cue Biopharma, Inc.v475194_ex10-6.htm
EX-10.4 - EXHIBIT 10.4 - Cue Biopharma, Inc.v475194_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - Cue Biopharma, Inc.v475194_ex10-3.htm
EX-10.1 - EXHIBIT 10.1 - Cue Biopharma, Inc.v475194_ex10-1.htm
EX-4.3 - EXHIBIT 4.3 - Cue Biopharma, Inc.v475194_ex4-3.htm
EX-3.3 - EXHIBIT 3.3 - Cue Biopharma, Inc.v475194_ex3-3.htm
EX-3.2 - EXHIBIT 3.2 - Cue Biopharma, Inc.v475194_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - Cue Biopharma, Inc.v475194_ex3-1.htm
S-1 - S-1 - Cue Biopharma, Inc.v475194_s1.htm

Exhibit 23.1

 

  

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

Cue Biopharma, Inc.

 

We hereby consent to the use in the Prospectus constituting a part of this Form S-1 Registration Statement of our report dated September 21, 2017, relating to the balance sheets of Cue Biopharma, Inc. (the “Company”) as of December 31, 2016 and 2015, and the related statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2016, which is contained in the Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

We also consent to the reference to us under the caption “Experts” in the Prospectus.

 

/s/ Gumbiner Savett Inc. 

September 21, 2017

Santa Monica, California

 

 

Cue Biopharma, Inc. Reports